1. Home
  2. FURY vs MGNX Comparison

FURY vs MGNX Comparison

Compare FURY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fury Gold Mines Limited

FURY

Fury Gold Mines Limited

HOLD

Current Price

$0.59

Market Cap

97.7M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.42

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FURY
MGNX
Founded
2008
2000
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.7M
94.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
FURY
MGNX
Price
$0.59
$1.42
Analyst Decision
Strong Buy
Hold
Analyst Count
2
5
Target Price
$1.40
$3.20
AVG Volume (30 Days)
554.5K
821.9K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$127,626,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.99
52 Week High
$0.89
$3.77

Technical Indicators

Market Signals
Indicator
FURY
MGNX
Relative Strength Index (RSI) 53.63 43.54
Support Level $0.50 $1.33
Resistance Level $0.63 $1.55
Average True Range (ATR) 0.05 0.11
MACD 0.01 0.01
Stochastic Oscillator 71.38 21.95

Price Performance

Historical Comparison
FURY
MGNX

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: